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Abstract
Background: India shoulders the greatest global burden of cardiovascular diseases (CVDs), which are the leading
cause of mortality worldwide. Drugs are the bedrock of treatment and prevention of CVD. India’s pharmaceutical
industry is the third largest, by volume, globally, but access to CVD drugs in India is poor. There is a lack of qualitative
data from government and pharmaceutical sectors regarding CVD drug development and access in India.
Methods: By purposive sampling, we recruited either Indian government officials, or pharmaceutical company
executives. We conducted a stakeholder analysis via semi-structured, face-to-face interviews in India. Topic guides allow
for the exploration of key issues across multiple interviews, along with affording the interviewer the flexibility to examine
matters arising from the discussions themselves. After transcription, interviews underwent inductive thematic analysis.
Results: Ten participants were interviewed (Government Officials: n = 5, and Pharmaceutical Executives: n= 5). Two
themes emerged: i) ‘Policy-derived Factors’; ii) ‘Patient- derived Factors’ with three findings. First, both government and
pharmaceutical participants felt that the focus of Indian pharma is shifting to more complex, high-quality generics and to
new drug development, but production of generic drugs rather than new molecular entities will remain a major activity.
Second, current trial regulations in India may restrict India’s potential role in the future development of CVD drugs. Third,
it is likely that the Indian government will tighten its intellectual property regime in future, with potentially far-reaching
implications on CVD drug development and access.
Conclusions: Our stakeholder analysis provides some support for present patent regulations, whilst suggesting areas for
further research in order to inform future policy decisions regarding CVD drug development and availability. Whilst
interviewees suggested government policy plays an important role in shaping the industry, a significant force for change
was ascribed to patient-derived factors. This suggests a potential role for Indian initiatives that market the unique
advantages of its patient population for drug research in influencing national and multinational pharmaceutical
companies to undertake CVD drug development in India, rather than simply IP policy-directed factors.
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Background
Cardiovascular Diseases (CVDs) are the principal
cause of deaths globally [40, 46, 47, 52] and global
spending on CVDs surpasses any other disease [3].
Low- and middle-income countries (LMICs) now
shoulder the majority of the global CVD burden [40];
no country more so than India, where ischaemic
heart disease (IHD) and stroke were the first and
eighth largest causes of years of life lost to death and
disability [14, 40]. The economic cost of CVD in India
is estimated at $30 billion per annum [32] with future
increases forecast [11, 21].
Drugs play an essential role in the prevention and treat-
ment of CVD and its risk factors [3]. Access to drugs plays
a significant part in reducing health inequality [12, 50, 51]
and is influenced by both affordability and availability [37].
The Indian pharmaceutical industry is now the 3rd largest,
by volume, in the world [31]. Furthermore, regardless of
recent regulatory changes due to concerns largely about
ethics, accountability and compensation [7], India remains
one of the world’s most attractive destinations for clinical
trials [6]. However, marked inequalities in CVD drug ac-
cess persist in India [43, 54] and improved access repre-
sents a key policy strategy.
Although prevalence studies from India suggested that
CVD was more common in urban than rural regions
[24], in more developed states of India such as Kerala,
the rural–urban differences in cardiometabolic risk fac-
tors have largely disappeared and the risk factors are
equal or slightly greater in rural subjects [38]. More than
70 % of India’s population lives in rural areas and nearly
40 % of the population is below the poverty line [38],
and CVD drugs are less likely to be taken in rural than
urban settings [30]. Barriers to CVD drug availability in
India include low utilization rates of evidence-based
therapies [34], high out-of-pocket expenditure, long dur-
ation of therapy and high drug costs relative to income
[37, 42]. The poorest are least likely to be able to afford
cardiovascular (or any) medications and out of pocket ex-
penditure on healthcare represents the highest proportion
of household spending in this group [16, 25]. Over 80 %
of CVD patients receive none of the recommended effect-
ive drug treatments [25] and low household wealth is the
most important determinant. A major portion of overall
out of pocket health spending (in excess of 45 %) is for
medicines for chronic diseases and this proportion was as
high as 64 and 58 % for cases of hypertension and dia-
betes, respectively [8, 19].
The Indian government spends just 1.2 % of the GDP
on the health sector, which is among the lowest in the
world [45]. Nearly 846 billion Indian rupees (INR) were
spent out of pocket on health care expenses in 2004,
amounting to 3.3 % of that year’s gross domestic product
(GDP). A major portion of overall out of pocket health
spending (in excess of 45 %) was for medicines
for NCDs and this proportion was as high as 64 and
58 % for cases of hypertension and diabetes, respect-
ively [19]. As a result of increasing realization of
health inequalities in terms of access to healthcare;
out-of-pocket expenditure and poverty caused by
healthcare expenditure; and an unsustainable national
pharmaceutical policy, the Indian government sanc-
tioned a $5.4-billion plan allowing government sector
doctors to prescribe generic drugs to patients free of
cost [20]. Generic medicines are typically 20 to 90 %
cheaper than originator equivalents [17, 49].
Given the importance of CVD, drugs for its treatment
and the scale of the Indian pharmaceutical sector, an evi-
dence base is crucial to inform policymakers in India.
Qualitative analyses of access to CVD drugs are very
limited in low- and low-middle income countries, in-
cluding India [29]. Government and pharmaceutical
companies have been previously identified as the most
powerful stakeholders in access to medicines [2]. There-
fore we conducted a stakeholder analysis of government
officials and pharmaceutical company executives regard-
ing development of and access to CVD drugs in India.
Aims
Among government officials and pharmaceutical company
executives, the aim was conduct a qualitative study to
understand the perceptions of the Indian government and
pharmaceutical industry about factors affecting the devel-
opment of new CVD drugs and access to CVD medicines.
Methods
Inclusion criteria
Interviewees were eligible for inclusion if they worked at
a policy-making level, either in a generation or advisory
capacity, in either:
i) The Indian government with reference to CVD
pharmaceuticals and/or healthcare (the Government
Official sub-group).
ii) A national or multi-national pharmaceutical com-
pany, with a base in India, involved in the develop-
ment of CVD medications (the Pharmaceutical
Executive sub-group).
In addition, participants had to be able to communi-
cate fluently in written and spoken English, and to pro-
vide informed, written consent.
Recruitment
Potential participants were contacted via e-mail, using
existing contacts. Convenience sampling therefore formed
a component of recruitment. However, strict adherence
to the inclusion criteria ensured a purposive sampling
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method, thereby mitigating against the reported inadequa-
cies of a solely convenience sampling approach [36, 41].
Once initial contact was made, informed consent was ob-
tained using documents structured in line with WHO
templates [53]. A conservative sample size of 12 partici-
pants was initially set [23].
Interviews
Semi-structured, face-to-face interviews were selected as
the most appropriate method of data collection for three
reasons. First, this technique allows interviewers to adapt
their communication in response to a participant’s behav-
ioural or verbal cue, enabling taxing subjects to be ad-
dressed. Second, this method requires a smaller sample
size than other qualitative methods [10], which was im-
portant given the expected difficulty in recruiting partici-
pants from government and pharmaceutical sectors.
Third, group-orientated qualitative research methods were
felt inappropriate for this study due to the potential for
business-sensitive information to arise in the discussions.
Topic guides allow for the exploration of key issues
across multiple interviews, along with affording the
interviewer the flexibility to examine matters arising
from the discussions themselves [5]. Moreover, semi-
structuring limits ‘dross rate’, defined by Holloway and
Wheeler [26] as information not relevant to the study.
Therefore, a topic guide asking open-ended questions
regarding three broad issues was constructed as a core
component of the semi-structuring of interviews for this
study (see Additional file 1). The three broad areas were:
(i) role of India in the development of CVD medications
both within India and throughout the world; (ii) influence
of India in the availability and development of CVD medi-
cations in the world pharmaceutical market; and (iii)
thoughts/beliefs on the pharmaceutical industry. The wide
nature of the points covered in this guide allowed the inter-
viewer the freedom to expand upon emerging themes as
they arose during the interviews. Issues were approached
from various time perspectives (past, present and future),
as an intentional attempt to draw upon the full length of an
interviewee’s experience in their field. All interviews were
undertaken in February and March 2015. Interviews were
undertaken at a location of the interviewee’s choice, in Eng-
lish. Each interview took place in an office environment in
New Delhi, Bangalore or Mumbai. Only the interviewer
and the participant were in each interview.
An audio recording was taken of all interviews. All in-
terviews aimed to last no longer than 30 min. The inter-
viewer would undertake all data analysis and was
therefore tasked with transcribing each recording verba-
tim. In doing this, they became habituated to the data
early on, a critical aspect of thematic analysis [9]. Audio
software was used to slow the recording during tran-
scription, in an attempt to reduce transcription error
rate. The interviewer then completed inductive thematic
analysis, as per the distinct 6-stage guidance outlined by
Braun and Clarke [9]. Following transcription, the inter-
viewer read through the entire dataset twice to ensure a
broad comprehension of the interviews was obtained. All
semantic and relevant latent themes were then coded
through line-by-line reading of the text, using NVivo 10
qualitative data analysis software. Semantic grouping of the
codes into candidate themes was then undertaken, forming
an initial thematic map (see Fig. 1). These themes were
then scrutinized for their legitimacy, as outlined by Braun
and Clarke [9], and to ensure their internal homogeneity
and external heterogeneity was present, as stipulated by
Patton [44]. Subsequent adaptation of the first thematic
map was required following this review process, resulting
in the production of a final thematic map (Fig. 2).
Member checking aims to ensure results presented in
qualitative analysis are both credible and reliable, avoiding
data misrepresentation [10]. It was felt appropriate to
complete this process, due to the potential for complex
topics to have arisen during the interviews in this re-
search. Therefore, after completing data analysis, the
interviewer e-mailed participants a summary of the initial
findings of their interview. Interviewees were asked to
check this summary, ensuring that their anonymity had
been preserved and nothing had been misinterpreted. No
issues of data misrepresentation arose from this process.
Inclusion of a detailed summation of the full analytical
process satisfies the assertion that “qualitative research is
reliable if one can follow the ‘decision trail’ of the inves-
tigative process” [39]. The transparency resulting from
the explicit account of the analytical process of this
study should, therefore, increase the reliability of these
findings, adding rigor to this research.
Results
Eleven interviewees were successfully recruited. Of those
recruited, one participant was excluded as it became
clear during the interview that they fell into neither one
of the stakeholder sub-groups, and were in fact from an
entirely clinical background. A final sample of 10 partici-
pants was therefore analysed, consisting of a Govern-
ment Official sub-group (n = 5) and Pharmaceutical
Executive sub-group (n = 5). The full participant recruit-
ment pathway can be seen in Fig. 3. Participant demo-
graphic data are shown in Table 1. Actual interview
times ranged from 28 to 46 min.
Responses to the issues outlined in the topic guide
(Additional file 1) were broad. However, there were rela-
tively few new viewpoints uncovered in the last inter-
view in each participant sub-group. Two distinct themes
emerged: i) Patient-derived Factors; ii) Policy-derived
Factors. Both emergent themes and their key topics are
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presented. Key issues are denoted as sub-headings under
their respective theme.
Theme 1: patient-derived factors
The first distinct theme that emerged from the data con-
tained factors that were either implicitly, or explicitly,
linked to the Indian patient population.
1 (a) clinical trial regulations
One participant suggested that the recent tightening of
clinical trial regulations in India was a positive factor af-
fecting the role India plays in the development of CVD
medicines:
P1 (Government Official sub-group): “The second
thing that has happened which is quite good is
tightening of [clinical trial] regulations… the patient
population do not get exploited with loose clinical
trial regulations.”
The suggestion made by Participant 1 was not unani-
mously supported. Other participants, from both
Fig. 1 The initial candidate thematic map. Numerous connections were present between the ‘Drug access’ and ‘Consumer’ themes, as well as the
‘Pharmaceutical Industry’ and ‘Indian Government’ themes
Fig. 2 Final thematic map showing the two externally
heterogeneous themes discussed in the ‘Results’ section Fig. 3 Full participant recruitment flowchart
Newman et al. Journal of Pharmaceutical Policy and Practice  (2016) 9:16 Page 4 of 11
stakeholder sub-groups, suggested that present regula-
tions applied too much pressure upon pharmaceutical
companies, and were likely to deter drug research and
development (R&D) in India:
P3 (Government Official sub-group): “It’s all negative
[referring to the role the Indian government plays in
relation to India’s pharmaceutical industry]… there are
three areas where we have problems with
government… one is the clinical trial regulatory regime…”
P6 (Pharmaceutical Executive sub-group): “The
regulatory body, that sits in the government… in the
last couple of years have come down with regulations
related to pharmaceutical industry, which were very
detrimental to the progress… on the clinical trial
front… it’s not possible to do studies with those
regulations in mind…”
The differences in opinions highlight the complexity of
the effects clinical trial regulations have had in India.
Tight clinical trial regulations to promote ethical re-
search may be motivated by concern for Indian patients,
however, these rules may have a detrimental effect on
the Indian pharmaceutical industry, according to partici-
pants in both stakeholder sub-groups.
1(b) benefits of undertaking drug development in India
Notwithstanding the conflicting opinion regarding drug
regulations in India, participants highlighted numerous
benefits to undertaking research in this nation. Firstly,
the lack of exposure to previous pharmacological inter-
ventions mitigates against confounders present in other
research settings, according to Participant 7:
P7 (Pharmaceutical Executive sub-group): “I think
what’s good about India is that there… are a lot of
drug naïve patients available… patients who have
never been treated with any drugs in the past… so…
historically speaking they have a clean slate… and
therefore… when you are looking for an effect of a
particular drug it’s much simpler because there are
no… confounders…”
This positive factor was not mentioned at all by the
Government Official sub-group, and introduced the idea
that the Indian patient population may convey a clinical
advantage over other nations, with reference to CVD
drug development. Participant 7 reported that a further
attraction for undertaking CVD medicine development
in India stemmed from the large Indian population.
They suggested the speed of research could be increased
due to ease of patient recruitment:
P7 (Pharmaceutical Executive sub-group): “Just by
sheer population… it’s possible to recruit patients
fast… drug development and discovery… can be
fast-forwarded… because of… this kind of [large]
number of patients that we have.”
This further example illustrates the importance
patient-derived factors have in influencing pharmaceut-
ical executive opinions regarding the best future focus
for their business.
1(c) role of the media
Patient-derived factors are not all positive with reference
to India’s development of CVD medicines. One partici-
pant highlights how unethical research may have
exploited patients in the past:
P10 (Pharmaceutical Executive sub-group): “…and
pharmaceutical industry… there are some bad players,
and there have been some practices within the industry
which were not the most ethical [towards patients] I
would say,”
Table 1 Participant Demographic Table
Participant ID Gender Age (years) Stakeholder sub-group Time Working in Respective sub-group (years)
P1 Male 34 Government Official 6
P2 Male 50 Government Official 2.5
P3 Male 74 Government Official 49
P4 Male 53 Government Official 10
P5 Male 52 Government Official 16.5
P6 Female 53 Pharmaceutical Executive 20
P7 Male 46 Pharmaceutical Executive 19
P8 Male 40 Pharmaceutical Executive 13
P9 Male 50 Pharmaceutical Executive 20
P10 Male 52 Pharmaceutical Executive 15
Participant demographics and ID numbers
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This interviewee went onto highlight the implicit role
the media plays, through incomplete reporting, in tar-
ring the wider reputation of the Indian pharmaceutical
industry:
P10 (Pharmaceutical Executive sub-group): “Having
said that [referring to their previous comment regarding
unethical research] I think… they [the pharmaceutical
industry] want to do the right thing. Unfortunately, I
think it is not publicised [to the patients] enough and…
it becomes more of… a whipping law… in terms of any
of the criticisms that come out…”
Therefore, whilst patient exploitation is not directly
patient-derived, the subsequent detrimental influence of
the media on patients is; through the resulting negative
opinions of the drug industry. Media was not mentioned
by the Government Official sub-group.
1(d) Patient Purchasing Power
Factors grounded in the patient population were com-
monly mentioned to affect availability of CVD medi-
cines. Firstly, the ability of patients to purchase CVD
medicines was highlighted as a significant barrier to
CVD drug affordability, by both stakeholder sub-groups:
P2 (Government Official sub-group): “Access is a
function of economic strength of the people… if they…
lack purchasing power, even if medicines are available in
the villages… they won’t be able to buy that
[CVD medicine].”
P7 (Pharmaceutical Executive sub-group): “I mean
large population of India still lives in its villages… the
poverty is just unbelievable… they don’t have money to
eat food, let alone have [CVD] medications.”
The contextualisation of poverty in terms of geo-
graphic location by Participant 7 echoes, to some extent,
the influence urbanisation has on access to CVD medi-
cines according to another interviewee. Here, difficulties
patients encounter in reaching government hospitals,
and therefore accessing the CVD medicines and treat-
ments available at these locations, is discussed:
P6 (Pharmaceutical Executive sub-group): “I mean
government hospitals are freely accessible… but even
multi-speciality government hospital is very far from
many of these rural areas, so many people will reach
there only when they are in very bad shape…”
Patient purchasing power and finances are therefore
somewhat linked to a person’s physical location, in rela-
tion to the dispenser-point of the CVD drugs.
1(e) patient education
Another frequently mentioned factor which influences
CVD drug access is educational level:
P8 (Pharmaceutical Executive sub-group): “From the
patient’s perspective, cardiovascular disease is something
which is a… chronic disease and it doesn’t… kill people in
a very short time. So I think that itself probably also
means that patients are not paying too much of attention
to the disease per se,”
P5 (Government Official sub-group): “There is a question
of [patient] education… better education… better lifestyle,
those things ensure… you understand how you need to go
for purchasing medicines.”
Participants from both sub-groups hence spoke of the
wider impact patient education has on their awareness
to acquire CVD drugs.
1(f) Non-conventional medicine use
A participant in the Government Official sub-group also
discussed the use of non-conventional medicine by pa-
tients, as a barrier to CVD drug access:
P5 (Government Official sub-group): “Also it’s [CVD
drug access] a question of belief… some of the people…
have the traditional way of thinking, so they do not go
by the modern [CVD] medicines…”
Therefore, participants felt that patient education in-
fluences CVD drug access, not only through patient mo-
tivation to obtain medicine, but also by influencing the
type of drugs being used. Patients may be harmed if al-
ternative therapies being used are less clinically effective
than conventional CVD drugs.
Theme 2: policy-derived factors
The second distinct theme that arose from this research
regarded issues that were grounded in Indian drug
policy.
2(a) Indian pharmaceutical industry focus and its effects
The predominant influence the Indian government has
had in the past, according to both stakeholder sub-
groups, is in directing the focus of the national pharma-
ceutical industry. Every participant stated the past, and
to a certain extent present, role of the Indian pharma-
ceutical industry is in the production of off-patent, gen-
eric medicines:
P2 (Government Official sub-group): “We [India] are
the generics industry. We are not so much engaged in
the new development of… [CVD] drugs.”
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P6 (Pharmaceutical Executive sub-group): “So I think
if you look at Indian pharmaceutical industry, largely
it’s generics based.”
Exploration of India’s current pharmaceutical focus
highlighted its role in the provision of low-cost, high
quality medicines for the developing world and the
West:
P3 (Government Official sub-group): “India could
continue to be a major supplier of quality medicine to the
third world countries, and also… in the West…”
P8 (Pharmaceutical Executive sub-group): “India has
impacted the global pharmaceutical industry a lot by
its generic drugs… provided to the global market,
whether it is US, Europe, or it is Sub-Saharan
countries….”
Furthermore, participants from both sub-groups touched
upon the prospective focus of the Indian CVD pharmaceut-
ical industry. Stakeholders stated the likely future for India
will be to produce more complex, high-quality generics and
to nurture stronger drug development:
P3 (Government Official sub-group): “…and within
generic, Indian industry’s also moving up the value
chain. So, instead of plain generics, they’re moving into
a complex, or different chain of generics…”
B4 (Government Official sub-group): “The Indian
pharmaceutical industry has largely been involved in
manufacturing generics… but they do have some new
fixed dose combinations and polypills which they
developed recently,”
P2 (Government Official sub-group): “We [India] are
the generics industry. We are not engaged in the new
development of… [CVD] drugs, but our… aim is that
[to become involved in the development of new CVD
drugs].”
Despite the predicted transition of focus in the Indian
industry, participants felt CVD generic medicines will
remain a significant player in this market for the foresee-
able future:
P10 (Pharmaceutical Executive sub-group): “…generics
will still continue to be the primary driver of the
[Indian pharmaceutical] market …”
One participant suggested the Indian generic industry
has cultivated an excessive amount of market competi-
tion, to the detriment of drug quality:
P10 (Pharmaceutical Executive sub-group): “The barriers
to entry are so low to make new… generic medicine in
India, you have got… 100 brands of atorvastatin now…
do you think all 100 brands are going to behave the
same way? Probably not… the quality control systems
that we invest in, in this facility [referring to their own
pharmaceutical company], are much more robust
than… some mum and pap making tablets… in a
garage…”
Participants also highlighted how generic CVD medi-
cines increase access, as they are an economically viable
option from a prescriber’s perspective:
P9 (Pharmaceutical Executive sub-group): “Generics
lower the cost of treatment, and hence give doctors the
choice to prescribe a generic drug, when otherwise they
may not have prescribed the innovator drug simply
because of cost…”
In summary, according to participants, the Indian
CVD pharmaceutical industry is currently centred on
large-scale generic production. This role is likely to
change in future to an increased focus on the production
of high-quality generics and undertaking more drug
R&D.
2(b) Indian human capital
Another significant impact government policy has had
on the Indian CVD drug industry, according to this
study’s participants, has been the increased availability of
scientific human capital:
P5 (Government Official sub-group): “Our Universities
are also good in terms of producing quality professionals,
and during the past 10 years a number of pharmacy
colleges have been set up… we have good quality of
professionals in the field of clinical trial and
pharmaceutical technology and pharmaceutical R&D,”
P6 (Pharmaceutical Executive sub-group): “One thing
which the [Indian] pharmaceutical industry has is lots
of very highly skilled manpower…”
The pool of skilled academics available to undertake
advanced drug research is therefore recognised by both
stakeholder sub-groups. Furthermore, one participant
implied this expert population is likely to grow, rather
than decrease, over coming years due to return of
trained Indian professionals to the country:
P8 (Pharmaceutical Executive sub-group): “You can
find that a lot of them [Indian men and women] have
gone abroad and specialized… in various
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[pharmaceutical] fields, even got work experience and
are willing to come back [to India]…”
2(c) attitude to product patent
Indian drug policy is also linked to access to CVD medi-
cines according this study’s participants. The inter-
national pharmaceutical community would apparently
prefer the Indian drug industry to have a more stringent
product patent regime. However, a major barrier to this
is product patent ‘Evergreening’, defined as a pharma-
ceutical company’s extension of their monopoly on a
drug beyond the usual term permitted by law [18].
Stakeholders form both sub-groups referred to this con-
troversial attitude to patent law:
P4 (Government Official sub-group): “The multinational
companies want a stronger patent regime in India… but
the Indian companies don’t want the multinational
companies to Evergreen…”
P7 (Pharmaceutical Executive sub-group): “You see
companies getting greedy… they have some small
incremental innovation, and they want now again 20
more years after… the main… patent has… expired… If
that can be prevented, then I think the basic intellectual
property should belong to those who invest money in it…”
Despite international pressure for India to tighten its
drug patent regime, one participant stated that India’s
present attitude to drug patents it not over-lenient, as it
conforms to the Trade-Related Aspects of Intellectual
Property Rights (TRIPS) agreement:
P3 (Government Official sub-group): “It’s [India’s product
patent regime] not lax, we are conforming to the TRIPS
agreement, whatever the standard TRIPS provided, we
conform to that…”
Instead of being down to laxities in India’s approach to
intellectual property (IP), this participant suggested the
international community were against India’s present IP
regime due to their success in producing high-quality
generic medicines for the developed world:
P3 (Government Official sub-group): “Now 80 % of
prescriptions in the US are of Indian generics, so the US
generic companies are hurt… when you are successful…
everyone is going to throw stone at you…”
Despite this defence of India’s existing attitude to IP, it
is likely that the Indian government will tighten regula-
tions in the near future, according to Participant 4. This
is due to the influence of other geo-political factors, like
the US’s provision of nuclear energy to India:
P4 (Government Official sub-group): “It’s… rumoured
that they [the Indian government] might have an
agreement with the US in terms of… tightening the
[drug] patent laws… to get other additional benefits…
nuclear energy treaty was held hostage to many other
things, so they [the Indian government] wanted to get
that off the ground,”
India’s compulsory licensing policy has allowed for past
overruling of product patents in order to increase access
to specific medicines. This initiative allows a government
to develop patented drugs, without the patent-holder’s
permission [13]. However, one participant suggested this
has detrimentally affected long-term access of novel CVD
medicines in India, through mistrust between multi-
national companies and the Indian government:
P6 (Pharmaceutical Executive sub-group): “They [the
Indian government] have asked the innovator… to give
up their patent… you are making it [the CVD drug]
available, but then… invalidating their [the innovator
company’s] patent in India… that will become a
deterrent for new CVD drugs to come to India.”
Therefore, there are perceived to be numerous exter-
nal pressures on India attempting to direct the govern-
ment’s future attitude regarding IP. Altering attitude to
IP may, through re-building trust with some multina-
tionals, increase the amount of new CVD products being
introduced into the Indian market, thereby potentially
improving CVD drug access.
Discussion
Our study highlights three findings. First, both government
and pharmaceutical participants felt that the focus of Indian
pharma is shifting to more complex, high-quality generics
and to new drug development, but production of generic
drugs rather than new molecular entities will remain a
major activity. Second, current trial regulations in India
may restrict India’s potential role in the future development
of CVD drugs. Third, it is likely that the Indian government
will tighten its intellectual property regime in future, with
potentially far-reaching implications on CVD drug develop-
ment and access.
The expiry of patents on $60 billion worth of drugs in
2010 suggests that India will remain a significant produ-
cer of generics [22]. The Indian pharmaceutical indus-
try’s increasing acquisition of resources to undertake
independent R&D make it likely that drug development
will gain in importance [27]. Whilst interviewees sug-
gested government policy plays an important role in
shaping the industry, a significant force for change was
ascribed to patient-derived factors, contrary to current
literature [27]. Therefore, there may be a potential role
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for Indian initiatives that market the unique advantages
of its patient population for drug research in influencing
national and multinational pharmaceutical companies to
undertake CVD drug development in India, rather than
simply IP policy-directed factors. It was suggested by
one interviewee that rapid patient recruitment repre-
sented a major advantage of undertaking research in
India. However, 2008 Federal Drug Administration
(FDA) data suggest that at inspected clinical trial sites,
China may be ahead of India in this regard, with India
and China recruiting 8 and 13 participants per recruit-
ment site respectively [33]. There is clearly a need for re-
search into the factors which make India attractive to
host CVD drug R&D before policy recommendations
can be made, and comparative research with China will
be beneficial to inform Indian policy [35].
Although current clinical trial regulations were impli-
cated in restricting Indian CVD drug development, there
are two arguments for their existence. First, deviations
from ethical research practice have been documented in
India previously [48] and therefore, more stringent regula-
tions protect Indian patients from recurrence of such ex-
ploitation [35], reiterated by one participant in this study.
Second, questions must be raised over the morality of
undertaking research with a population that ultimately
may not have access to the final product; such as in India
where CVD drug availability is an issue. A fine line there-
fore exists, regarding clinical trial guidelines, between
market facilitation and patient protection. However, it is
clear that participants felt that the present balance is
weighed against the CVD drug development industry. As
with other heath policy domains, there is a role for an in-
dependent evidence-based appraisal of present clinical
trial regulations in India [4] support the use of formal ana-
lytical institutes for the of health policy in LMICs, to en-
sure adequate patient protection, while allowing Indian
pharmaceutical development.
Whilst one participant defended India’s current stance,
asserting that the government rigorously conform to
TRIPS guidelines, other interviewees outlined the exter-
nal pressure being placed on India to observe to tighter
patent regulations. The European Union’s Free Trade
Agreement states Europe’s intentions to seek regulations
that go beyond the TRIPS agreement in developing
countries [15]. Succumbing to such demands may afford
India benefits to other sectors, such as energy, according
to one stakeholder. Although IP regulations are praised in
India for driving the development of a stronger R&D sec-
tor within the Indian pharmaceutical industry [27], there
has been a lack of technology transfer since India’s signing
of the TRIPS agreement in 1992, along with a diminished
focus on drug production as per the needs of the national
population [1]. However, continued adherence to existing
IP regulations may help reinforce trust between the Indian
government and multinational drug industry, which is
suspicious due to India’s past compulsory licensing [28].
An improved relationship could persuade pharmaceutical
companies to make novel CVD medicines readily available
on the Indian market, something that they are presently
reluctant to do according to this study. Further policy re-
search should investigate the effects of tighter IP control
and tighter clinical trial regulations on the scale of drug
development in India.
Limitations
The small sample size of this study is a limitation. How-
ever, few novel topics emerged during the final interview
of each stakeholder sub-group, suggesting theoretical
saturation was being approached. Triangulation, the use
of multiple researchers for data analysis [10], was not
possible, and would have increased the validity of our
findings. Our analysis considered two specific stake-
holder subgroups in the Indian context for CVD drugs,
and therefore, our findings cannot be generalized to
other subgroups, countries or drug areas.
Conclusion
Among government and pharmaceutical stakeholders, our
analysis suggested consensus around three barriers to new
CVD drug development and access in India: (i) the pre-
vailing culture, expertise and infrastructure of the drug in-
dustry favouring generic production; (ii) strict clinical trial
regulations; and (iii) the current IP regime. The role of
these different factors on CVD drug development and ac-
cess in India should be the subject of further research.
Key messages
1. Both government and pharmaceutical participants
felt that the focus of Indian pharma is shifting to
more complex, high-quality generics and to new
drug development, but production of generic drugs
rather than new molecular entities will remain a
major activity.
2. Current trial regulations in India may restrict India’s
potential role in the future development of CVD drugs.
3. It is likely that the Indian government will tighten
its intellectual property regime in future, with
potentially far-reaching implications on CVD drug
development and access.
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